Role of genetic polymorphisms in drug metabolizing cytochrome P450 enzymes expressed in the brain for affective disorders

Recruiting

• Conditions: F32; F31; F33; F34; F38; F39; Bipolar affective disorder; Depressive episode; Recurrent depressive disorder; Persistent mood [affective] disorders

• Registration Number: DRKS00011722
• Lead Sponsor: Bundesinstitut für Arzneimittel und Medizinprodukte

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2017-02-15
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

Written consent to the study
- Age restriction: 18-50 years
- Healthy to shlightly reduced general condition (ASA 1-2)
- BMI over 18 kg/m²
- Good german language skills
- Willingness and suitability for an MRI examination

Exclusion Criteria

- In women: Pregancy or breastfeeding period
- Reduced general health condition
- Regular drug ingestion (with the exception of Thyroxin (Euthyreose), Statins, ACE-Inhibitiors or oral contraceptives)
- Metal implates (for example: pacemaker, copper spiral (in women), claustrophobia)
- other contraindications for nuclear resonance imaging
- consent incapable
- Indication for neurological or psychatric diseases
- No appropriate knowledge of german language to work on the questionnaires
- not-to-know incidental findings

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The aim of the present research project is to investigate the role of CYPs in healthy participants to the vulnerability to mental disorders through their action on endogenous substrates in the brain and their resulting effects on brain morphology and function.